Novocure Stock Price, News & Analysis

Novocure (NASDAQ: NVCR) has achieved a significant milestone as Spain's Ministry of Health approves coverage of Tumor Treating Fields (TTFields) therapy through the Spanish National Health System (SNS) for adult patients with newly diagnosed glioblastoma.

TTFields therapy, which uses electric fields to disrupt cancer cell division through a wearable medical device, has received CE Mark approval for treating WHO Grade 4 Glioma. The treatment is now commercially available in multiple countries across North America, Europe, and Asia, with reimbursement established in eight countries including Austria, France, Germany, Israel, Japan, Sweden, Switzerland, and the United States. To date, over 35,000 patients globally have received TTFields treatment.

Novocure (NASDAQ: NVCR) has submitted a premarket approval (PMA) application to the FDA for its Tumor Treating Fields (TTFields) therapy to treat locally advanced pancreatic cancer. The application is backed by the successful PANOVA-3 trial, which demonstrated statistically significant improvement in median overall survival for patients treated with TTFields combined with standard chemotherapy.

The trial data was featured at the 2025 ASCO Annual Meeting in the "Best of ASCO" program and published in the Journal of Clinical Oncology. The PMA was submitted as a Panel-Track Supplement to Optune Lua® and is expected to be converted to a separate original PMA, with an approval decision anticipated in second half of 2026.

Novocure (NASDAQ: NVCR) reported Q2 2025 financial results with total net revenues of $158.8 million, up 6% year-over-year. The company maintained 4,331 active patients on Tumor Treating Fields (TTFields) therapy globally.

Key financial metrics include a 74% gross margin and a net loss of $40.1 million ($0.36 per share). The company maintains a strong cash position of $911.5 million.

Significant clinical progress includes the presentation of successful Phase 3 PANOVA-3 trial results at ASCO 2025, showing statistically significant extension in overall survival for pancreatic cancer patients. The company plans FDA submissions for pancreatic cancer treatment in Q3 2025 and brain metastases from NSCLC in H2 2025.

Novocure (NASDAQ: NVCR) will present final secondary endpoint data from its Phase 3 PANOVA-3 trial at the ESMO Gastrointestinal Cancers Congress 2025. The trial evaluated Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel (GnP) for treating unresectable, locally advanced pancreatic cancer.

The study demonstrated significant improvements in multiple quality of life metrics: Global health status deterioration was delayed to 7.1 months vs. 5.7 months (p=0.023), pain deterioration was extended to 10.1 months vs. 7.4 months (p=0.003), and pancreatic pain deterioration was prolonged to 14.7 months vs. 10.2 months (p=0.006) compared to GnP alone.

Additionally, the trial showed significant delay in first opioid use (7.1 months vs. 5.4 months, p=0.046) and improved pain-free survival (15.2 months vs. 9.1 months, p=0.027). TTFields therapy was well-tolerated with mild to moderate skin adverse events being the most common device-related side effects. The company plans to submit a premarket application to the FDA in the second half of 2025.

Novocure (NASDAQ: NVCR) has scheduled its second quarter 2025 financial results announcement for July 24, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss its financial performance for the three and six-month periods ending June 30, 2025.

The presentation materials will be accessible through Novocure's investor relations website and will remain available for at least 14 days after the call. The company uses its investor relations website to disclose material non-public information in compliance with Regulation FD.

Zai Lab and Novocure announced positive Phase 3 PANOVA-3 trial results for Tumor Treating Fields (TTFields) therapy in pancreatic cancer treatment. The trial, combining TTFields with gemcitabine and nab-paclitaxel, demonstrated significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The study showed median overall survival of 16.2 months versus 14.2 months in the control group (HR 0.82; p=0.039). Notable improvements included one-year survival rate (68.1% vs 60.2%) and pain-free survival (15.2 vs 9.1 months). The therapy was well-tolerated with only mild to moderate skin adverse events. Novocure plans to submit data to FDA in second half of 2025 for premarket approval. The results will be presented at the 2025 ASCO Annual Meeting and published in the Journal of Clinical Oncology.

Novocure (NVCR) announced positive Phase 3 PANOVA-3 trial results for its Tumor Treating Fields (TTFields) therapy in pancreatic cancer, showing significant improvement in overall survival. When combined with gemcitabine and nab-paclitaxel, TTFields therapy demonstrated a median overall survival of 16.2 months versus 14.2 months in the control group (HR 0.82; p=0.039). The therapy showed notable improvements in one-year survival rates (68.1% vs 60.2%) and pain-free survival (15.2 vs 9.1 months). Quality of life metrics also improved significantly, with better outcomes in global health status, pain management, and digestive problems. The treatment was well-tolerated with only mild to moderate skin adverse events. Novocure plans to submit these results to the FDA in H2 2025 for premarket approval, with additional submissions planned for EU, Japan, and other markets.

Novocure (NVCR) has announced two upcoming investor events. The company will host a PANOVA-3 Investor Event on May 31, 2025, at 8:00 p.m. ET in Chicago to discuss data from their successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Dr. Vincent Picozzi, a medical oncologist and trial investigator, will join the leadership team to review results.

Additionally, CEO Ashley Cordova will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. ET. CFO Christoph Brackmann will join for one-on-one investor meetings. Both events will be webcast and available for replay on Novocure's website.

Novocure (NVCR) reported Q1 2025 financial results with net revenues of $155.0 million, up 12% year-over-year. The company achieved 4,268 active patients on Tumor Treating Fields therapy globally as of March 31, 2025.

Key financial metrics include: 75% gross margin, net loss of $34.3 million ($0.31 per share), and cash position of $929.1 million. Regional revenue contributions: US ($93.2M), Germany ($18.7M), France ($17.9M), and Japan ($8.7M).

Notable developments include CE Mark approval for Optune Lua for metastatic NSCLC treatment and upcoming presentation of Phase 3 PANOVA-3 pancreatic cancer trial results at ASCO 2025. The company faces potential tariff impacts of up to $8-11 million in 2025 depending on policy implementation.